260 related articles for article (PubMed ID: 36972361)
1. Revisiting Androgen Receptor Signaling in Breast Cancer.
Dai C; Ellisen LW
Oncologist; 2023 May; 28(5):383-391. PubMed ID: 36972361
[TBL] [Abstract][Full Text] [Related]
2. Selective Androgen Receptor Modulator RAD140 Inhibits the Growth of Androgen/Estrogen Receptor-Positive Breast Cancer Models with a Distinct Mechanism of Action.
Yu Z; He S; Wang D; Patel HK; Miller CP; Brown JL; Hattersley G; Saeh JC
Clin Cancer Res; 2017 Dec; 23(24):7608-7620. PubMed ID: 28974548
[No Abstract] [Full Text] [Related]
3. Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide.
Cochrane DR; Bernales S; Jacobsen BM; Cittelly DM; Howe EN; D'Amato NC; Spoelstra NS; Edgerton SM; Jean A; Guerrero J; Gómez F; Medicherla S; Alfaro IE; McCullagh E; Jedlicka P; Torkko KC; Thor AD; Elias AD; Protter AA; Richer JK
Breast Cancer Res; 2014 Jan; 16(1):R7. PubMed ID: 24451109
[TBL] [Abstract][Full Text] [Related]
4. Androgen receptor signaling pathways as a target for breast cancer treatment.
Pietri E; Conteduca V; Andreis D; Massa I; Melegari E; Sarti S; Cecconetto L; Schirone A; Bravaccini S; Serra P; Fedeli A; Maltoni R; Amadori D; De Giorgi U; Rocca A
Endocr Relat Cancer; 2016 Oct; 23(10):R485-98. PubMed ID: 27528625
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological Targeting of Androgen Receptor Elicits Context-Specific Effects in Estrogen Receptor-Positive Breast Cancer.
Wei L; Gao H; Yu J; Zhang H; Nguyen TTL; Gu Y; Passow MR; Carter JM; Qin B; Boughey JC; Goetz MP; Weinshilboum RM; Ingle JN; Wang L
Cancer Res; 2023 Feb; 83(3):456-470. PubMed ID: 36469363
[TBL] [Abstract][Full Text] [Related]
6. Androgen receptor mediated growth control of breast cancer and endometrial cancer modulated by antiandrogen- and androgen-like steroids.
Hackenberg R; Schulz KD
J Steroid Biochem Mol Biol; 1996 Jan; 56(1-6 Spec No):113-7. PubMed ID: 8603031
[TBL] [Abstract][Full Text] [Related]
7. [Dual effects of androgens on mammary gland].
Brettes JP; Mathelin C
Bull Cancer; 2008 May; 95(5):495-502. PubMed ID: 18541513
[TBL] [Abstract][Full Text] [Related]
8. Selective androgen receptor modulators (SARMs) negatively regulate triple-negative breast cancer growth and epithelial:mesenchymal stem cell signaling.
Narayanan R; Ahn S; Cheney MD; Yepuru M; Miller DD; Steiner MS; Dalton JT
PLoS One; 2014; 9(7):e103202. PubMed ID: 25072326
[TBL] [Abstract][Full Text] [Related]
9. Targeting the androgen receptor in breast cancer.
Chia K; O'Brien M; Brown M; Lim E
Curr Oncol Rep; 2015 Feb; 17(2):4. PubMed ID: 25665553
[TBL] [Abstract][Full Text] [Related]
10. The androgen receptor is a tumor suppressor in estrogen receptor-positive breast cancer.
Hickey TE; Selth LA; Chia KM; Laven-Law G; Milioli HH; Roden D; Jindal S; Hui M; Finlay-Schultz J; Ebrahimie E; Birrell SN; Stelloo S; Iggo R; Alexandrou S; Caldon CE; Abdel-Fatah TM; Ellis IO; Zwart W; Palmieri C; Sartorius CA; Swarbrick A; Lim E; Carroll JS; Tilley WD
Nat Med; 2021 Feb; 27(2):310-320. PubMed ID: 33462444
[TBL] [Abstract][Full Text] [Related]
11. Androgen Receptor Expression and Bicalutamide Antagonize Androgen Receptor Inhibit β-Catenin Transcription Complex in Estrogen Receptor-Negative Breast Cancer.
Huang R; Han J; Liang X; Sun S; Jiang Y; Xia B; Niu M; Li D; Zhang J; Wang S; Wei W; Liu Q; Zheng W; Zhang G; Song Y; Panga D
Cell Physiol Biochem; 2017; 43(6):2212-2225. PubMed ID: 29069648
[TBL] [Abstract][Full Text] [Related]
12. The interplay of endocrine therapy, steroid pathways and therapeutic resistance: Importance of androgen in breast carcinoma.
Takagi K; Miki Y; Ishida T; Sasano H; Suzuki T
Mol Cell Endocrinol; 2018 May; 466():31-37. PubMed ID: 28918115
[TBL] [Abstract][Full Text] [Related]
13. Androgen deprivation by adrenal suppression using low-dose hydrocortisone for the treatment of breast carcinoma with apocrine features: a case report illustrating this new paradigm.
Jongen L; Paridaens R; Floris G; Wildiers H; Neven P
Breast Cancer Res Treat; 2016 Feb; 155(3):603-7. PubMed ID: 26868122
[TBL] [Abstract][Full Text] [Related]
14. Sex steroid induced apoptosis as a rational strategy to treat anti-hormone resistant breast and prostate cancer.
Jordan VC; Fan P; Abderrahman B; Maximov PY; Hawsawi YM; Bhattacharya P; Pokharel N
Discov Med; 2016 May; 21(117):411-27. PubMed ID: 27355337
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer.
Gucalp A; Tolaney S; Isakoff SJ; Ingle JN; Liu MC; Carey LA; Blackwell K; Rugo H; Nabell L; Forero A; Stearns V; Doane AS; Danso M; Moynahan ME; Momen LF; Gonzalez JM; Akhtar A; Giri DD; Patil S; Feigin KN; Hudis CA; Traina TA;
Clin Cancer Res; 2013 Oct; 19(19):5505-12. PubMed ID: 23965901
[TBL] [Abstract][Full Text] [Related]
16. Targeting androgen receptor in estrogen receptor-negative breast cancer.
Ni M; Chen Y; Lim E; Wimberly H; Bailey ST; Imai Y; Rimm DL; Liu XS; Brown M
Cancer Cell; 2011 Jul; 20(1):119-31. PubMed ID: 21741601
[TBL] [Abstract][Full Text] [Related]
17. The growth response to androgen receptor signaling in ERα-negative human breast cells is dependent on p21 and mediated by MAPK activation.
Garay JP; Karakas B; Abukhdeir AM; Cosgrove DP; Gustin JP; Higgins MJ; Konishi H; Konishi Y; Lauring J; Mohseni M; Wang GM; Jelovac D; Weeraratna A; Sherman Baust CA; Morin PJ; Toubaji A; Meeker A; De Marzo AM; Lewis G; Subhawong A; Argani P; Park BH
Breast Cancer Res; 2012 Feb; 14(1):R27. PubMed ID: 22321971
[TBL] [Abstract][Full Text] [Related]
18. The potential clinical benefit of targeting androgen receptor (AR) in estrogen-receptor positive breast cancer cells treated with Exemestane.
Amaral C; Augusto TV; Almada M; Cunha SC; Correia-da-Silva G; Teixeira N
Biochim Biophys Acta Mol Basis Dis; 2020 May; 1866(5):165661. PubMed ID: 31891807
[TBL] [Abstract][Full Text] [Related]
19. Androgen receptor: A promising therapeutic target in breast cancer.
Vasiliou SK; Diamandis EP
Crit Rev Clin Lab Sci; 2019 May; 56(3):200-223. PubMed ID: 30821186
[TBL] [Abstract][Full Text] [Related]
20. Androgen and oestrogen receptor co-expression determines the efficacy of hormone receptor-mediated radiosensitisation in breast cancer.
Michmerhuizen AR; Lerner LM; Ward C; Pesch AM; Zhang A; Schwartz R; Wilder-Romans K; Eisner JR; Rae JM; Pierce LJ; Speers CW
Br J Cancer; 2022 Sep; 127(5):927-936. PubMed ID: 35618789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]